AR054522A1 - Moduladores lxr basados en pirazol - Google Patents

Moduladores lxr basados en pirazol

Info

Publication number
AR054522A1
AR054522A1 ARP060102762A ARP060102762A AR054522A1 AR 054522 A1 AR054522 A1 AR 054522A1 AR P060102762 A ARP060102762 A AR P060102762A AR P060102762 A ARP060102762 A AR P060102762A AR 054522 A1 AR054522 A1 AR 054522A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
cycloalkyl
heteroaryl
independently
Prior art date
Application number
ARP060102762A
Other languages
English (en)
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37309323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054522(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AR054522A1 publication Critical patent/AR054522A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen composiciones farmacéuticas que contienen los compuestos, así como los métodos de utilizacion de dichos compuestos. Reivindicacion 1: Un compuesto de acuerdo con una de las formulas (1) a (4), o una sal, isomero o profármaco farmacéuticamente aceptable del mismo, en donde, A) R1 representa -L1-R5, en donde: L1 es un union, L5, L6, -L5-L6-L5-, o -L6-L5-L6-, en donde: cada L5 es independientemente -[C(R15)2]m-, donde, cada R15 es independientemente hidrogeno, halogeno, alquilo C1-6, o haloalquilo C1-6; cada L6 es independientemente -C(R11)2-, -C(R11)2C(R11)2-, -C(R11)=C(R11)-, -C(R11)2O-, -C(R11)2NR11-, -C:::C-, -O-, -S-, -NR11-, -N(R10)CO-, - N(R10)CO2-, -CON(R10)-, -CO-, -CS-, -CO2-, -OC(=O)-, -OC(=O)N(R10)-, - CONR11N(R11)2-, -CONR11-, -OCONR11-, -SO2-, -N(R10)SO2-, - SO2N(R10), -NR10CONR10-, -NR10CSNR10-, -C(=NR11)-, -C(=NOR11)-, -C(=NN(R1)2)-, arilo-, cicloalquilo C3-8, ciclo-haloalquiloC3-8, heteroarilo, heterociclilo, donde el arilo, cicloalquilo, ciclo-haloalquiloC3-8, heteroarilo, o heterociclilo son opcionalmente sustituidos con uno o más radicales de R14; o L1 representa una cadena de alidiilo C2-6 donde la cadena de alidiilo es opcionalmente interrumpida por -C(R11)2-, - C(R11)2C(R11)2-, - C(R11)=C(R11)-, -C(R11)2O-, -C(R11)2NR11-, -C:::C-, -O-, -S-, -N(R10)CO-, -N(R10)CO2-, -CON(R10)-, -CO-, -CO2-, - OC(=O)-, -OC(=O)N(R10)-, -SO2-, -N(R10)SO2-, o -SO2N(R10)-; R5 representa arilo, heterociclilo, heteroarilo, alquenilo C2-6, alquinilo C2-6, cicloalquiloC3-8-alquiloC1-6-, cicloalqueniloC3-8-alquiloC1-6-, cicloalquiloC3-8-alqueniloC2-6, cicloalquilo C3-8, -C, -B-C, -A-B-C, donde, a representa -O-; B representa -[C(R15)2]m- o cicloalquilo C3-8; C representa alquilo C1-6, haloalquilo C1-6, -SO2R11, -SR11, -SO2N(R11)2, - SO2NR11COR11, -C:::N, C(O)OR11, CON(R11)2 o N(R11)2, donde R5 es opcionalmente sustituido con uno o más R5a, en donde cada R5a es independientemente alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquiniloC3-8-alquiloC1-6-, cicloalqueniloC3-8- alquiloC1-6-, cicloalquiloC3-8-alqueniloC2-6-, halogeno, nitro, heterocicli-oxi, arilo, ariloxi, arilalquilo, ariloxiarilo, aril-alcoxiC1-6, -C', -B-C', o - A'-B'-C' en donde A' es -O-; B representa -[C(R15)2]m- o cicloalquilo C3-8-; C' es -H, halogeno, -SO2R11, -OR11, -SR11, -N3, -COR11, - SO2N(R11)2, -SO2NR11COR11, -C:::N, -C(O)OR11, -OC(=O)R11, -CON(R11)2, -CON(R11)OR11, -OCON(R11)2, -NR11COR11, -NR11CON(R11) 2, -NR11COOR11, -N(R11)2, arilo, heteroarilo, o heterociclilo; en donde cada R5 se sustituye de manera opcional con uno o más grupos que son independientemente alquenilo C2-6, alquinilo C2-6, cicloalquiloC3-8-alquiloC1-6-, cicloalqueniloC3-8-alquiloC1-6-, cicloalquiloC3-8- alqueniloC2-6-, alcoxiarilo C0-6, alquilo C1-6, cicloalquilo C3-8, arilohalogeno, -C:::N, -COR11, -COOR11, -CON(R11)2, -SO2R11, -OR11, -SR11, -SO2R11, -SO2N(R11)2, -SO2NR11COR11, -OCON(R11)2; -NR11COR11, -NR11CON(R11)2, -NR11COOR11, o -N(R11)2; 2 y R21 son -L3-R7, en donde: cada L3 es independientemente un enlace o -V1-(CH2)n-V1-, -(CH2)m-V1-(CH2)n- en donde, n es 0-6; y cada V1 es independientemente -C(R11)2-, -C(R11)2C(R11)2-, -C(R11)=C(R11)-, -C(R11)2O-, -C(R11)2NR11-, -C:::C-, -O-, -S-, - NR7-, -N(R10)CO-, - N(R10)CO2-, -OCO-, -CO-, -CS-, -CONR10-, -C(=N-R11)-, -C(=N-OR11)-, -C[=N-N(R11)2], -CO2-, -OC(=O)-, -OC(=O)N(R10)-, -SO2-, -N(R10) SO2-, -SO2N(R10)-, -NR10CONR10-, -NR10CSNR10-, cicloalquilo C3-8, o ciclohaloalquilo C3-8; o cada L3 es independientemente una cadena alidiilo C2-6, en donde la cadena de alidiilo es opcionalmente interrumpida por -C(R11)2-, -C(R11)2C(R11)2-, -C(R11)=C(R11)-, -C(R11)2O-, - C(R11)2NR11-, -C:::C-, -O-, -S-, -N(R10)CO-, -N(R10)CO2-, -CON(R10)-, -CO- , -CO2-, -OC(=O)-, -OC(=O)N(R10)-, -SO2-, -N(R10)SO2-, o - SO2N(R10)-; y cada R7 es independientemente un hidrogeno, halogeno, nitro, arilo, heteroarilo, heterociclilo, -alquiloC1-6-heterociclilo, - alquiloC1-6-heteroarilo, -alquiloC1-6-arilo, -Z, -Y- Z, o -X-Y-Z, en donde, X es -O-; Y es -[C(R15)2]m-, -alqueniloC2-6, -cicloalquiloC3-8; Z es - H, -CN, halogeno, -OR11, -C(=O)R11, -C(=O)OR11, -C(=O)N(R11)2, -N(R11)2, -CN, -N3, -SO2R11, -S(=O)2N(R11)2, -C(=O)N(R11)N(R11)2, - C(=O)N(R11)(OR11), -OC(=O)- R11, -OC(=O)-N(R11)2, o -N(R11)COOR11, en donde R7 se sustituye de manera opcional con uno o más R7a, en donde, R7a es un halogeno, alquenilo C2-6, -alquiloC1-6-heterociclilo, -alquiloC1-6-heteroarilo, -alquiloC1-6-arilo, alcoxiheteroarilo C0-6, alcoxiheterociclilo C0-6, haloarilo, ariloxi, aralquil-oxi, ariloxialquilo, alcoxiarilo C1-6, ariloC0-6-alquilocarboxi, C(R11)=C(R11)-COOOR11, alcoxiheteroarilo C0-6, alcoxiheterociclilo C0-6, arilo, heteroarilo, heterociclilo, cicloalquilo C3-8, heteroarilo-oxi, -Z', -Y'-Z', o-X'-Y'-Z', en donde , X' es -O-; Y' es -[C(R15)2]m- o cicloalquilo C3-8; Z' es -alquiloC1-6, -haloalquiloC1-6, -OR11, -SR11, -S(=O)2R11, -C(=O)R11, -C(=O)OR11, - C(=O)N(R11)2, -N(R11)2, -N(R11)C(=O)R11, - S(=O)2N(R11)C(=O)R11, -CN, -S(=O)2N(R11)2, -C(=O)N(R11)N(R11)2, -C(=O)N(R11)(OR11), - OC(=O)-R11, -OC(=O)-OR11, -N(R11)C(=O)-R11, -N(R11)S(O=)2R11; en donde cada R7a se sustituye de manera opcional con uno o más R8, en donde cada R8 es independientemente un halogeno, nitro, ciano, heteroarilo, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, haloalquiloC1- C6(OR11), alquilC0-C6OR11, alquiloC0-C6CON(R11)2, alquiloC0-6COR11, alquiloC0-C6COOR11, o alquiloC0-C6SO2R1, y en donde si dos R7a se presentan en el mismo carbono, se pueden combinar para formar un grupo heterociclilo o cicloalquilo; siempre que R2 y R21 no sean de manera simultánea -H; R3 es -L-R6, en donde, L es un enlace, -X3-(CH2)n-X3-, -(CH2)m-X3-(CH2)n- o -(CH2)1+w-Y3- (CH2)w-, en donde, n es 0-6; cada w es independientemente 0-5; y cada X3 es independientemente un enlace, -C(R11)2-, -C(R11)2C(R11)2-, -C(R11)=C(R11)-, -C:::C-, -CO-, -CS-, -CONR10-, -C(=N)(R11)-, -C(=N-OR11)-, -C[=N-N(R11)2], -CO2-, -SO2-, o - SO2N(R10)-; y Y3 es -O-, -S-, -NR7-, -N(R10)CO-, - N(R10)CO2-, -OCO-, -OC(=O)N(R10)-, -NR10CONR10-, -N(R10)SO2-, o -NR10CSNR10-; o L es una cadena de alidiilo C2-6 en donde la cadena de alidiilo se interrumpe de manera opcional por -C(R11)2-, - C(R11)2C(R11)2, -C(R11)=C(R11)-, -C(R11)2O-, -C(R11)2NR11-, -C:::C-, -O-, - S-, -N(R10)CO-, -N(R10)CO2-, -CON(R10)-, -CO-, -CO2-, -OC(=O)-, -OC(=O)N(R10)-, -SO2-, -N(R10)SO2-, o -SO2N(R10); y R6 es alquilo C1-6, haloalquilo C1-6, arilo, cicloalquilo C3-8, heteroarilo, heterociclilo, -CN, -C(=O)R11, -C(=O)OR11, -C(=O)N(R11)2, -N(R11)2, -SO2R11, -S(=O) 2N(R11)2, -C(=O)N(R11)N(R11)2, -C(=O)N(R11)(OR11), en donde el arilo, heteroarilo, cicloalquilo, o heterociclilo se sustituyen de manera opcional con uno o más R6a, en donde cada R6a es independientemente -Z'',-Y''-Z'', o -X''-Y''-Z'', en donde: X'' es -O-; Y'' es -[C(R15)2]m-, - alqueniloC2-6, cicloalquilo C3-8, heterociclilo, arilo, o heteroarilo, en donde el arilo, heteroarilo, cicloalquilo, o heterociclilo se sustituye de manera opcional con al menos un grupo independiente de Z''; Z'' es -H, -CN, halogeno, -OR11, -C(=O)R11, -C(=O)OR11, -C(O)N(R11)2, - N(R11)2, -N3, -SO2R11, -S(=O)2N(R11)2, -C(=O)N(R11)N(R11)2, - N(R11)C(=O)N(R11)2, -OC(=O)-R11, -C(=O)N(R11)(OR11), -OC(=O)-R11, - OC(=O)-N(R11)2, o -N(R11)COOR11; cada R10 es independientemente -R11, -C(=O)R11, -CO2R11, o -SO2R11; cada R11 es independientemente -hidrogeno, alqueniloC2-6, alquinilo C2-6, cicloalqueniloC3-8-alquiloC1-6-, cicloalquiloC3-8-alqueniloC2-6, N(R12)2, alquilo C1-6, -haloalquiloC1-6, -cicloalquiloC3-8, -alquiloC1-6-cicloalquiloC3-8, arilo, -alquiloC1-6-arilo, heteroarilo, -alquiloC1-6-heteroarilo, heterociclilo, o -alquiloC1- 6-heterociclilo; en donde cualquiera de los R11 se los sustituye de manera opcional con uno o más radicales R12; cada R12 es independientemente un halogeno, haloalquilo C1-6, alquilo C1-6, alcoxi C1-6, (alquiloC0-6)C=O(OR13); alquiloC0-6OR13, alquiloC0-6COR13, alquiloC0-6SO2R13, alquiloC0-6CN, alquiloC0-6CON(R13)2, alquiloC0-6CONR13OR13, alquiloC0-C6SO2N(R13)2, alquiloC0-6SR13, haloalquilC0-6OR13, ariloxi, aralquil-oxi, ariloxialquilo, alcoxiarilo C0-6, arilo-alquilcarbonC0-6-oxi, alquiloC0-6NR13SOR13, - alquiloC0-C6N(R13)2, o -OalquiloC0-6COOR13; cada R13 es independientemente un hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquiloC3-8-alquiloC1-6-, cicloalqueniloC3-8-alquiloC1-6-, o cicloalquiloC3-8- alqueniloC2-6-; cada R14 es independientemente alquilo C1-6, alcoxi C1-6, halogeno, haloalquilo C1-6, alquiloC0-6CON(R11)2, alquiloC0-6CONR11OR11, alquiloC0-6OR11, o alquiloC0-6COOR11; G es un grupo de la formula (5), en donde: J es arilo, heteroarilo, o se encuentra ausente; K es arilo, heteroarilo, o se encuentra ausente; cada R4 es independientemente un halogeno, nitro, alquenilo C2-6, cicloalquilo C3-8, -alquiloC1-6-heterociclilo, -alquiloC1-6-heteroarilo, -alquiloC1-6-arilo, - heterociclil-arilo, -heterociclil-heteroarilo, CR11=CR11COOR11, ariloxi, -S-arilo, aralquiloxi, ariloxialquilo, alcoxiarilo C1-6, arilo- alquilcarboxiC0-6, alcoxiheteroarilo C0-6, alcoxiheterociclilo C0-6, arilo, heteroarilo, heterociclilo, -M, -E-M, o -D-E-M, en donde: D es -O-; E es -[C(R15)2]m- o -cicloalquiloC3-8; M es -alquiloC1-6, haloalquilo C1-6, -COR11, -COOR11, -OC(=O)R11, -CON(R11)2, -C:::N, -OR11, - OCON(R11)2, -OCO2-R11, -N3, -NR11COR11, -NR11SO2R11, -N(R11)2, -NR11COOR11, -SOR11, - SO2R11, -SO2NR11COR11, -SO2N(R11)2, o - SR11; en donde cada R4 se sustituye de manera opcional con uno o más R4a, en donde cada R4a es independientemente halogeno, ariloxi, aralquiloxi, ariloxialquilo, alcoxiarilo C1-6, aril-alquilcarbonoC0-C6-oxi, - M', -E'-M', o -D'-E'-M', en donde D' es -O-; E' es -[C(R15)2]m- o cicloalquilC3-C8; M' es -alquiloC1-6, haloalquilo C1-6, -COR11, -CON(R11)2, -N(R11)COOR11, -N(R11)2, COOR11, C:::N, OR11, NR11COR11, NR11SO2R11, SO2R11, SO2N(R11)2, o SR11; cada R41 es independientemente un halogeno, nitro, alquiloC1-6-heterociclilo, -alquiloC1-6- heteroarilo, -alquiloC1-6-arilo, -M'', -E''-M'',
ARP060102762A 2005-06-27 2006-06-27 Moduladores lxr basados en pirazol AR054522A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69437205P 2005-06-27 2005-06-27
US73612005P 2005-11-10 2005-11-10

Publications (1)

Publication Number Publication Date
AR054522A1 true AR054522A1 (es) 2007-06-27

Family

ID=37309323

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060102761A AR054521A1 (es) 2005-06-27 2006-06-27 Moduladores de lxr basados en imidazol
ARP060102762A AR054522A1 (es) 2005-06-27 2006-06-27 Moduladores lxr basados en pirazol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP060102761A AR054521A1 (es) 2005-06-27 2006-06-27 Moduladores de lxr basados en imidazol

Country Status (18)

Country Link
US (3) US8569352B2 (es)
EP (2) EP1910307A1 (es)
JP (2) JP5237799B2 (es)
KR (2) KR20080028964A (es)
AR (2) AR054521A1 (es)
AU (2) AU2006261841B8 (es)
BR (1) BRPI0612287A8 (es)
CA (2) CA2613517A1 (es)
ES (1) ES2525217T3 (es)
IL (1) IL188239A0 (es)
MX (1) MX2008000141A (es)
MY (1) MY152162A (es)
NO (1) NO20080391L (es)
NZ (1) NZ564916A (es)
PE (2) PE20070187A1 (es)
SG (1) SG162804A1 (es)
TW (2) TW200745045A (es)
WO (2) WO2007002563A1 (es)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE313532T1 (de) 2003-07-22 2006-01-15 Arena Pharm Inc Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
CA2613517A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
NZ595571A (en) 2006-02-28 2013-04-26 Helicon Therapeutics Inc Pyrazole compounds and uses thereof
EP1989188B1 (en) 2006-02-28 2015-07-22 Dart Neuroscience (Cayman) Ltd Therapeutic piperazines as pde4 inhibitors
AU2013200480B2 (en) * 2006-02-28 2016-06-09 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
US8148418B2 (en) 2006-05-18 2012-04-03 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
CN102827081A (zh) 2006-05-18 2012-12-19 艾尼纳制药公司 用作5-ht2a 血清素受体调节剂的苯基-吡唑的晶型和其制备方法
JP5406018B2 (ja) 2006-05-18 2014-02-05 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ａセロトニンレセプターに関連する障害の処置に有用な５−ｈｔ２ａセロトニンレセプターのモジュレーターとしての１級アミン、およびその誘導体
EP3231442B1 (en) 2006-06-23 2019-12-25 ADC Therapeutics SA Polynucleotides and polypeptide sequences involved in cancer
TWI408136B (zh) * 2006-10-02 2013-09-11 Nat Health Research Institutes 噻吩化合物及其醫藥組成物
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US8193225B2 (en) * 2006-10-13 2012-06-05 The Board Of Regents Of The University Of Texas System Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
JP5399262B2 (ja) 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒおよびｆｘｒのモジュレーター
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008113255A1 (fr) * 2007-03-16 2008-09-25 The Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques
AU2008253311A1 (en) * 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellshaft Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CN101687790B (zh) * 2007-05-25 2015-02-11 Abbvie公司 作为代谢型谷氨酸受体2(mglu2受体)的正向调节剂的杂环化合物
EP2176409B1 (en) * 2007-07-11 2012-01-04 Yeda Research And Development Co. Ltd. Nucleic acid construct systems capable of diagnosing or treating a cell state
CA2695517C (en) * 2007-08-03 2016-09-20 J. Edward Semple Alkylsulfonyl-substituted thiazolide compounds
WO2009023253A2 (en) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
MX2010002258A (es) 2007-08-27 2010-04-22 Helicon Therapeutics Inc Compuestos terapeuticos de isoxazol.
AU2008296974B2 (en) * 2007-09-06 2013-10-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
US8063088B2 (en) * 2008-06-11 2011-11-22 Hoffmann-La Roche Inc. Imidazolidine derivatives
RS57110B1 (sr) 2008-10-28 2018-06-29 Arena Pharm Inc Sastavi modulatora 5-ht2a serotoninskog receptora korisni za tretiranje poremećaja povezanih sa njim
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
BRPI0921805A2 (pt) 2008-11-03 2016-11-01 Alethia Biotherapeutics Inc anticorpos que especificamente bloqueiam a atividade biológica de um antígeno de tumor
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
BRPI1006896B1 (pt) 2009-01-30 2022-05-24 Novartis Ag Cloridrato de n-{(1s)-2-amino-1-[(3-fluorfenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h- pirazol-5-il)-2-tiofenocarboxamida cristalino, composição farmacêutica compreendendo o mesmo e uso do dito composto para tratar ou diminuir a gravidade de câncer e artrite
AU2010218224B2 (en) * 2009-02-26 2013-06-27 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2607348B8 (en) 2009-03-31 2021-04-21 Renascience Inc. Plasminogen Activator Inhibitor-1 Inhibitor
KR101760956B1 (ko) * 2009-05-12 2017-07-24 로마크 레버러토리즈, 엘.씨. 할로알킬 헤테로아릴 벤즈아미드 화합물
CA2761934C (en) * 2009-05-28 2018-01-09 Exelixis Patent Company Llc Substituted 1-(biphenyl-4-yl)-2-benzyl-4-hydroxyalkyl-1h-imidazole compounds and their use as lxr modulators
JP5932640B2 (ja) 2009-06-26 2016-06-08 ロマーク ラボラトリーズ エル．シー． インフルエンザを治療するための化合物および方法
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
AU2011248579A1 (en) 2010-04-27 2012-11-29 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) * 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
MX2012013774A (es) 2010-05-27 2012-12-17 Merck Sharp & Dohme Activadores de guanilato ciclasa soluble.
WO2012003405A1 (en) 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
JP5722891B2 (ja) 2010-07-15 2015-05-27 大日本住友製薬株式会社 ピラゾール化合物
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
CN103153300A (zh) 2010-08-11 2013-06-12 米伦纽姆医药公司 杂芳基化合物和其用途
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
KR101901741B1 (ko) 2010-09-07 2018-10-01 서울대학교산학협력단 세스터터핀 화합물 및 이들 물질의 용도
AU2011316016A1 (en) 2010-10-13 2013-05-30 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MX341531B (es) 2010-11-09 2016-08-22 Ironwood Pharmaceuticals Inc Derivados de triazol como estimuladores de la guanilato ciclasa soluble gcs.
ES2883274T3 (es) * 2011-03-08 2021-12-07 Sagimet Biosciences Inc Moduladores heterocíclicos de la síntesis de lípidos
AR088728A1 (es) * 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
DK2691421T3 (en) 2011-03-31 2017-02-20 Alethia Biotherapeutics Inc ANTIBODIES AGAINST NON-REFERENCE ANTIGEN 1 AND ANTIGIN BINDING FRAGMENTS
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
BR112013033316A2 (pt) 2011-06-24 2017-01-31 Amgen Inc antagonista de trpm8 e seu uso em tratamentos
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
DE102011055815A1 (de) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
CA2861804C (en) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
DK2802351T3 (da) 2012-01-09 2019-05-13 Adc Therapeutics Sa Midler til behandling af triple-negativ brystkræft
BR112014021515A2 (pt) * 2012-03-02 2018-03-13 Alexar Therapeutics, Inc. moduladores de receptor x hepático (lxr) para o tratamento de doenças, distúrbios e condições de pele
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
US8859781B2 (en) * 2012-07-12 2014-10-14 Euclises Pharmaceuticals, Inc. No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents
EP2877464B1 (en) * 2012-07-24 2016-08-24 Boehringer Ingelheim International GmbH N-cyclopropyl-n-piperidinyl-amide derivatives and their use as gpr119 modulators
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
CA2882292C (en) 2012-08-13 2023-10-17 The Rockefeller University Treatment and diagnosis of melanoma
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
WO2014037327A1 (en) * 2012-09-10 2014-03-13 Boehringer Ingelheim International Gmbh N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof
CN102924347A (zh) * 2012-11-21 2013-02-13 徐州宇家化工科技有限公司 苯基甲基砜衍生物的制备方法
MX2015008919A (es) 2013-01-10 2015-10-22 Gruenenthal Gmbh Carboxamidas basadas en pirazolilo i como inhibidores del canal de calcio activado por liberacion de calcio (crac).
EA201500737A1 (ru) 2013-01-10 2016-04-29 Грюненталь Гмбх Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
CN105102448B (zh) 2013-02-28 2018-03-06 百时美施贵宝公司 作为rock1和rock2抑制剂的苯基吡唑衍生物
CN105188380B (zh) 2013-03-15 2017-08-15 百时美施贵宝公司 Lxr调节剂
AU2014232383B2 (en) * 2013-03-15 2019-01-17 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
JP6442475B2 (ja) * 2013-03-15 2018-12-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
EP2990057B1 (en) 2013-04-15 2019-03-20 Renascience Co., Ltd. Pai-1 inhibitor for use in enhancing the antitumor effect of an antitumor agent in a patient
WO2014199164A1 (en) * 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds
SI3041835T1 (sl) * 2013-09-04 2020-09-30 Ellora Therapeutics, Inc. Modulatorji jetrnih X receptorjev (LXR)
WO2015035027A1 (en) * 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators
CN103588758A (zh) * 2013-11-04 2014-02-19 南京大学 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用
US9231217B2 (en) 2013-11-28 2016-01-05 Semiconductor Energy Laboratory Co., Ltd. Synthesis method of organometallic complex, synthesis method of pyrazine derivative, 5,6-diaryl-2-pyrazyl triflate, light-emitting element, light-emitting device, electronic device, and lighting device
MA39147B1 (fr) 2013-12-17 2019-12-31 Esteve Labor Dr Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma
CN106061969B (zh) 2014-01-06 2019-10-29 阿尔戈么迪克斯有限公司 Trpa1调节剂
CA2939120A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
AR101816A1 (es) 2014-04-02 2017-01-18 Bayer Cropscience Ag Derivados de 3-[(pirazol-5-il)-heteroaril]-benzamidas como agentes pesticidas
EP3154954B1 (en) * 2014-06-10 2022-02-09 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
WO2015197187A1 (en) 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides v
US10112939B2 (en) 2014-08-21 2018-10-30 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
MX2017016413A (es) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
DK3395801T3 (da) * 2015-12-16 2021-05-10 Nippon Soda Co Arylazolforbindelse og skadedyrsbekæmpelsesmiddel
US11648220B2 (en) 2016-01-11 2023-05-16 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
WO2017147523A1 (en) * 2016-02-26 2017-08-31 The Regents Of The University Of California Small molecule inhibitors of pendrin ion exchange and pharmaceutical compositions
EP3490579A1 (en) 2016-07-27 2019-06-05 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
US11498903B2 (en) 2017-08-17 2022-11-15 Bristol-Myers Squibb Company 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases
JP2021504315A (ja) 2017-11-21 2021-02-15 ルジェニクス，インコーポレーテッド 多形及びその使用
CA3089134A1 (en) 2018-01-29 2019-08-01 Capulus Therapeutics, Llc Srebp inhibitors comprising a 6-membered central ring
WO2019165158A1 (en) * 2018-02-22 2019-08-29 University Of Florida Research Foundation, Incorporated Il-6 inhibitors and methods of treatment
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN113631163A (zh) * 2019-01-28 2021-11-09 卡普勒斯疗法有限责任公司 包括噻吩中心环的srebp抑制剂
CN114728875A (zh) 2019-12-13 2022-07-08 因思博纳公司 金属盐及其用途
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
CA3166630A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
CN115461083A (zh) * 2020-03-02 2022-12-09 塔夫茨大学信托人 用于在体内向免疫细胞递送mRNA的基于咪唑的合成类脂质
WO2023004280A1 (en) * 2021-07-19 2023-01-26 The Board Of Trustees Of The Leland Stanford Junior University Selective pyrazole lrrk2 inhibitors and methods for use thereof

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US655563A (en) * 1900-03-03 1900-08-07 Hewitt Lindstrom Motor Company Electric carriage.
GB1510107A (en) * 1974-05-23 1978-05-10 Sandoz Products Ltd Benzimidazolyl-furan derivatives and use thereof as optical brighteners
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS5726653A (en) 1980-05-09 1982-02-12 Ciba Geigy Ag Substituted phenyl ether
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US4559394A (en) 1983-06-03 1985-12-17 Phillips Petroleum Company Olefin polymerization using activated chromium catalyst treated with tertiary alcohol
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL82856A0 (en) 1986-06-26 1987-12-20 Norwich Eaton Pharma Pharmaceutical compositions containing 2-(5-phenyl-2-furanyl)imidazoles and certain such novel compounds
US4895867A (en) 1986-06-26 1990-01-23 Norwich Eaton Pharmaceuticals, Inc. 2-(5-phenyl-2-furanyl)imidazoles useful as cardiotonic agents
US5221623A (en) 1986-07-22 1993-06-22 Boyce Thompson Institute For Plant Research, Inc. Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5070012A (en) 1988-03-30 1991-12-03 The Board Of Trustees Of The Leland Stanford Junior University Monitoring of cells and trans-activating transcription elements
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5283179A (en) 1990-09-10 1994-02-01 Promega Corporation Luciferase assay method
ATE215601T1 (de) 1991-09-17 2002-04-15 Salk Inst For Biological Studi Rezeptoren der steroid/thyroid superfamilie von rezeptoren
US6492411B1 (en) 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
RO118291B1 (ro) 1993-11-30 2003-04-30 Searle & Co Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine
JPH09504111A (ja) 1993-12-30 1997-04-22 ザ ソールク インスチチュート フォア バイオロジカル スタディズ Ｇａｌ４−受容体構築体の新規な使用
JP3466765B2 (ja) 1994-07-27 2003-11-17 キッコーマン株式会社 ビオチン化ホタルルシフェラーゼ、ビオチン化ホタルルシフェラーゼ遺伝子、新規な組み換え体ｄｎａ、ビオチン化ホタルルシフェラーゼの製造法及び生物発光分析法
WO1996014302A1 (en) * 1994-11-08 1996-05-17 Eisai Co., Ltd. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
US5747661A (en) 1995-01-13 1998-05-05 Howard Hughes Medical Institute Retinoid-inducible response elements
US6005086A (en) 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5955604A (en) 1996-10-15 1999-09-21 The Regents Of The University Of California Substrates for β-lactamase and uses thereof
ATE224878T1 (de) * 1996-11-04 2002-10-15 Aventis Cropscience Sa 1-polyarylpyrazole als pestizide
CN1248916A (zh) 1997-01-24 2000-03-29 加利福尼亚大学董事会 FXR、PPARα和LXRα激活剂恢复屏障功能、促进表皮分化和抑制增生的用途
US20020035156A1 (en) 1997-04-18 2002-03-21 Barbara Roniker Combination therapy in the prevention of cardiovascular disorders
AU4229999A (en) * 1998-06-05 1999-12-20 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
EP1115853A2 (en) 1998-09-23 2001-07-18 Ludmila Solomin Analysis of ligand activated nuclear receptors in vivo
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
JP4221129B2 (ja) 1999-02-15 2009-02-12 富士フイルム株式会社 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子
US6071955A (en) 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
DE60013417T2 (de) 1999-03-26 2005-09-15 City Of Hope, Duarte Verfahren zum screenen von fxr-rezeptormodulatoren
DK1177187T3 (da) 1999-04-28 2007-10-15 Sanofi Aventis Deutschland Diarylsyrederivater som PPAR-receptorligander
CN1379817A (zh) 1999-06-18 2002-11-13 Cv治疗公司 使用atp结合框运输蛋白abc1增加胆固醇排放并提高hdl的组合物及方法
AU6074700A (en) 1999-07-08 2001-01-30 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
IL150069A0 (en) 1999-12-06 2002-12-01 Sangamo Biosciences Inc Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
AU2000235960A1 (en) 2000-02-14 2001-08-27 Tularik, Inc. Lxr modulators
US6627647B1 (en) 2000-03-23 2003-09-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
AU2001262984A1 (en) 2000-05-03 2001-11-12 Tularik, Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
JP4803946B2 (ja) 2000-05-29 2011-10-26 杏林製薬株式会社 置換フェニルプロピオン酸誘導体
WO2002088107A1 (en) * 2001-04-26 2002-11-07 Eisai Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
IL158693A0 (en) 2001-05-09 2004-05-12 Sumitomo Chem Takeda Agro Co Azole compounds, process for preparation of the same and use thereof
US7101910B2 (en) 2001-06-12 2006-09-05 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
AR036608A1 (es) 2001-09-24 2004-09-22 Bayer Corp Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad
CA2458661A1 (en) * 2001-09-27 2003-04-03 Applied Research Systems Ars Holding N.V. Methods of increasing endogenous testosterone levels
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US6555563B1 (en) 2001-11-16 2003-04-29 Medinox, Inc. Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
DK1482931T3 (da) 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
AU2003238667B2 (en) * 2002-04-05 2006-07-20 Cadila Healthcare Limited 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
CA2485679A1 (en) * 2002-04-08 2003-10-23 The Ohio State University Research Foundation Compounds and methods for inducing apoptosis in proliferating cells
MXPA04009961A (es) * 2002-04-12 2004-12-13 Pfizer Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
AU2003263814A1 (en) 2002-07-26 2004-02-16 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
AU2003260345A1 (en) 2002-07-31 2004-02-23 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
US7109227B2 (en) 2002-08-26 2006-09-19 National Health Research Institutes Imidazolamino compounds
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
AU2003270446A1 (en) * 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
JP2004137270A (ja) 2002-09-26 2004-05-13 Nippon Nohyaku Co Ltd 新規除草剤、その使用方法、新規置換チエノピリミジン誘導体及びその中間体並びにそれらの製造方法
JP4631259B2 (ja) 2002-10-03 2011-02-16 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子及び表示装置
AU2003271117A1 (en) * 2002-10-09 2004-05-04 Ssp Co., Ltd. Novel pyrazole compounds having antifungal activity
AU2003287965A1 (en) * 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
AU2003287912A1 (en) 2002-12-20 2004-07-14 Novo Nordisk A/S Dicarboxylic acid derivatives as ppar-agonists
EP1581523B1 (en) * 2002-12-23 2009-09-30 Sanofi-Aventis Deutschland GmbH Pyrazole-derivatives as factor xa inhibitors
US7396850B2 (en) 2003-01-06 2008-07-08 Eli Lilly And Company Pyrazole derivative as PPAR modulator
DE602004030318D1 (de) 2003-01-27 2011-01-13 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
EP1594847A2 (en) * 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
JP4590825B2 (ja) * 2003-02-21 2010-12-01 コニカミノルタホールディングス株式会社 白色発光有機エレクトロルミネッセンス素子
CA2512886A1 (en) * 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
US20050113423A1 (en) * 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
WO2004089303A2 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
DE10315571A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
DE10315569A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
DE10315573A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
EP1631568A1 (en) * 2003-04-18 2006-03-08 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
JP2007503469A (ja) * 2003-05-20 2007-02-22 トランス　テック　ファーマ，インコーポレイテッド アミロイド症およびそれに関連した疾患を改善するための作用物質としてのｒａｇｅアンタゴニスト
BRPI0410623A (pt) 2003-05-27 2006-06-20 Sod Conseils Rech Applic composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
EP1648876A1 (en) 2003-07-24 2006-04-26 Pharmagene Laboratories Ltd 5-ht sb 2b /sb receptor antagonists
CA2532231A1 (en) 2003-07-25 2005-02-03 Pfizer Inc. Aminopyrazole compounds and use as chk1 inhibitors
WO2005044130A1 (en) * 2003-10-03 2005-05-19 The Ohio State University Research Foundation Pdk-1/akt signaling inhibitors
WO2005037199A2 (en) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
US7608639B2 (en) 2003-10-14 2009-10-27 Eli Lilly And Company Phenoxyether derivatives as PPAR modulators
US20070060629A1 (en) 2003-10-17 2007-03-15 Yasuhiro Imanishi Large conductance calcium-activated k channel opener
ES2298832T3 (es) * 2003-10-24 2008-05-16 Glaxo Group Limited Compuestos heterociclicos.
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
CA2547212A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US20050148601A1 (en) 2003-12-19 2005-07-07 Maynard George D. Neurokinin-3 receptor modulators: diaryl imidazole derivatives
EP1740211A2 (en) * 2004-04-20 2007-01-10 Pfizer Products Incorporated Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
WO2006014005A1 (ja) 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. ピラゾール誘導体
JP2006104191A (ja) 2004-09-07 2006-04-20 Sankyo Co Ltd 置換ビフェニル誘導体
WO2006028029A1 (ja) 2004-09-07 2006-03-16 Sankyo Company, Limited 置換ビフェニル誘導体
AU2005295753A1 (en) * 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
CA2594488C (en) 2005-01-10 2015-04-28 University Of Connecticut Novel heteropyrrole analogs acting on cannabinoid receptors
AU2006205220B2 (en) * 2005-01-10 2012-09-13 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
BRPI0609464A2 (pt) 2005-05-23 2010-04-13 Japan Tobacco Inc composto de pirazol e agente terapêutico para diabetes compreendendo o mesmo
CA2613517A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
JP5399262B2 (ja) * 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒおよびｆｘｒのモジュレーター

Also Published As

Publication number Publication date
KR101363278B1 (ko) 2014-02-21
US8569352B2 (en) 2013-10-29
WO2007002559A1 (en) 2007-01-04
KR20080028964A (ko) 2008-04-02
NZ564916A (en) 2011-03-31
PE20070105A1 (es) 2007-02-06
EP1910308A1 (en) 2008-04-16
JP2008543971A (ja) 2008-12-04
WO2007002559A8 (en) 2008-01-31
JP2008543970A (ja) 2008-12-04
MY152162A (en) 2014-08-15
AU2006261841B2 (en) 2012-06-07
US9000022B2 (en) 2015-04-07
US20100075964A1 (en) 2010-03-25
WO2007002563A1 (en) 2007-01-04
KR20080039381A (ko) 2008-05-07
TW200745045A (en) 2007-12-16
US20100331295A1 (en) 2010-12-30
AU2006261841B8 (en) 2012-12-06
TWI388323B (zh) 2013-03-11
JP5237799B2 (ja) 2013-07-17
SG162804A1 (en) 2010-07-29
EP1910308B1 (en) 2014-09-03
AU2006261845C1 (en) 2013-05-16
EP1910307A1 (en) 2008-04-16
IL188239A0 (en) 2008-04-13
AR054521A1 (es) 2007-06-27
AU2006261845B2 (en) 2012-09-13
CA2613522A1 (en) 2007-01-04
AU2006261841A1 (en) 2007-01-04
TW200738641A (en) 2007-10-16
NO20080391L (no) 2008-03-19
CA2613517A1 (en) 2007-01-04
JP5244589B2 (ja) 2013-07-24
AU2006261845A1 (en) 2007-01-04
ES2525217T3 (es) 2014-12-19
PE20070187A1 (es) 2007-03-09
MX2008000141A (es) 2008-04-07
US20140038964A1 (en) 2014-02-06
BRPI0612287A2 (pt) 2011-03-15
BRPI0612287A8 (pt) 2019-01-22
US8703805B2 (en) 2014-04-22

Similar Documents

Publication Publication Date Title
AR054522A1 (es) Moduladores lxr basados en pirazol
AR027406A1 (es) Moduladores de receptores canabinoides, sus procesos de preparacion y uso de los moduladores de receptores canabinoides para el tratamiento de enfermedadesrespiratorias y no respiratorias.
ES2238091T3 (es) Compuestos metalocenos sustituidos para sistemas catalizadores de polimerizacion de olefinas, sus productos intermedios y metodos para su preparacion.
EA200300813A1 (ru) Огнезащитные реагенты
DE60208364D1 (de) Chinolinderivate mit einer azolylgruppe und chinazolinderivate
HUP0002729A2 (hu) 4-(Halogén-alkil)-3-heterociklusos-piridin- és 4-(halogén-alkil)-5-heterociklusos-pirimidin-származékok, eljárás előállításukra, ezeket tartalmazó készítmények és kártevőírtó szerként történő alkalmazásuk
ATE196634T1 (de) Hydrolisierbare und polymerisierbare silane
DK1583524T3 (da) Bis(thiohydrazidamid)-forbindelser til behandling af multilægemiddel-resistent cancer
AR077010A1 (es) Benzimidazoles, benzotiazoles y benzoxazoles sustituidos
WO2003024441A1 (fr) Nouvelle utilisation de composes tricycliques
DE50014944D1 (de) Hydrolysierbare und polymerisierbare silane
WO2006021655A3 (fr) Dérivés doxopiperidine, leur préparation et leur application en thérapeutique
DE602004013938D1 (de) Hemmstoffe des ep4-rezeptors
DK1717229T3 (da) Ny cyklisk forbindelse med 4-pyridylalkylthiogruppe med deri indført (u)substitueret amino
AR072118A1 (es) Derivados de pirrolidina como antagonistas de receptor de nk2
KR970001378A (ko) 전이금속 화합물
AR042002A1 (es) Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central.
NO961085L (no) Androsteroner
AR039119A1 (es) Derivados de fenil amidas siliconadas utiles como microbiocidas
WO2005011697A3 (en) Sulfonamide derivatives with activity on protein kinase a and b
CO5700831A2 (es) Compuestos de silicio con actividad microbiocida
SE0401001D0 (sv) Chemical process
JP2003530400A5 (es)
KR950002760A (ko) 안압 강하제
KR870005969A (ko) 살충성 화합물의 제조 방법

Legal Events

Date Code Title Description
FA Abandonment or withdrawal